<p>Turn Therapeutics Inc.（納斯達克代碼：TTRX - 獲取免費報告）董事 Arthur Golden 於 11 月 24 日星期一購買了 9,868 股 Turn Therapeutics 股票。該股票的平均購買成本為每股 3.44 美元，總交易額為 33,945.92 美元。收購完成後，該董事直接持有公司 60,602 股股票，估值約為 208,470.88 美元。此次交易使其持股增加了 19.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過此鏈接獲取。</p>
<p>獲取 <strong>Turn Therapeutics</strong> 警報：</p>
<h2>Turn Therapeutics 價格表現</h2>
<p>TTRX 股票在週二下跌 0.20 美元，達到 3.30 美元。該公司的股票交易量為 82,657 股，而其平均交易量為 109,339 股。Turn Therapeutics Inc.的 1 年最低價為 2.57 美元，1 年最高價為 26.50 美元。</p>
<p>Turn Therapeutics（納斯達克代碼：TTRX - 獲取免費報告）最近於 11 月 13 日星期四發佈了季度財報。公司報告該季度每股收益為（0.07）美元。</p>
<h2>Turn Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家制藥和醫療器械開發公司，圍繞一種專有平台技術構建，旨在增強藥物性能。我們的專利混合工藝——商業上稱為 PermaFusion™（“PermaFusion”）——能夠在不使用乳化劑的情況下，將極性水溶性活性藥物成分（“API”）穩定懸浮在油基載體中。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Turn Therapeutics</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>什麼是標準普爾 500 指數，它與其他指數有何不同</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>標準普爾 500 指數在 12 月會反彈嗎？這三個信號指向重大變動</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Turn Therapeutics 嗎？</h2>
<p>在考慮 Turn Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Turn Therapeutics 並不在名單上。</p>
<p>雖然 Turn Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TTRX

<p>Turn Therapeutics 董事 Arthur Golden 購買了 9,868 股，增加了 19.45% 的持股比例。該交易的價值為 33,945.92 美元，並在 SEC 備案中披露。股票價格下跌了 0.20 美元，至 3.30 美元，交易量為 82,657 股。Turn Therapeutics 報告的季度每股收益為（-0.07 美元）</p>

<p>Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction dated Monday, November 24th. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $33,945.92. Following the completion of the acquisition, the director directly owned 60,602 shares of the company's stock, valued at approximately $208,470.88. The trade was a 19.45% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Turn Therapeutics Inc.（納斯達克代碼：TTRX - 獲取免費報告）董事 Arthur Golden 於 11 月 24 日星期一購買了 9,868 股 Turn Therapeutics 股票。該股票的平均購買成本為每股 3.44 美元，總交易額為 33,945.92 美元。收購完成後，該董事直接持有公司 60,602 股股票，估值約為 208,470.88 美元。此次交易使其持股增加了 19.45%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過此鏈接獲取。</p>
</div><p>Get <strong>Turn Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Turn Therapeutics</strong> 警報：</p>
</div><h2>Turn Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Turn Therapeutics 價格表現</h2>
</div><p>Shares of TTRX stock traded down $0.20 on Tuesday, reaching $3.30. The company's stock had a trading volume of 82,657 shares, compared to its average volume of 109,339. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50.</p>
<div class="lb-trans"><p>TTRX 股票在週二下跌 0.20 美元，達到 3.30 美元。該公司的股票交易量為 82,657 股，而其平均交易量為 109,339 股。Turn Therapeutics Inc.的 1 年最低價為 2.57 美元，1 年最高價為 26.50 美元。</p>
</div><p>Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.</p>
<div class="lb-trans"><p>Turn Therapeutics（納斯達克代碼：TTRX - 獲取免費報告）最近於 11 月 13 日星期四發佈了季度財報。公司報告該季度每股收益為（0.07）美元。</p>
</div><h2>Turn Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Turn Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.</p>
<div class="lb-trans"><p>我們是一家制藥和醫療器械開發公司，圍繞一種專有平台技術構建，旨在增強藥物性能。我們的專利混合工藝——商業上稱為 PermaFusion™（“PermaFusion”）——能夠在不使用乳化劑的情況下，將極性水溶性活性藥物成分（“API”）穩定懸浮在油基載體中。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Turn Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Turn Therapeutics</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>華納兄弟出售傳聞升温：投資者需要知道什麼</li>
<li>什麼是標準普爾 500 指數，它與其他指數有何不同</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>標準普爾 500 指數在 12 月會反彈嗎？這三個信號指向重大變動</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Turn Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Turn Therapeutics 嗎？</h2>
</div><p>Before you consider Turn Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Turn Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Turn Therapeutics 並不在名單上。</p>
</div><p>While Turn Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Turn Therapeutics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Turn Therapeutics（NASDAQ:TTRX）的董事購買了價值 33,945.92 美元的股票